The clinical importance of proton pump inhibitor pharmacokinetics

Digestion

Volumn 66, Issue 2, 2002, Pages 67-78

  Yacyshyn, Bruce R ^a,b   Thomson, A B R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Duodenal ulcer; Gastric ulcer; Proton pump inhibitors; Reflux disease

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; PROTON PUMP; SULFOXIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DUODENUM ULCER; GASTROESOPHAGEAL REFLUX; HUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ULCER; COST CONTROL; DRUG ANTAGONISM; METABOLISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; COST SAVINGS; DUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 0036432798     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065588     Document Type: Review

References (93)

1. Fitton A, Wiseman L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-482.
2. Benet LZ, Zech K: Pharmacokinetics - A relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994;8(suppl 1):25-32.
3. Clissold SP, Campoli-Richards DM: Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15-47 [published erratum appears in Drugs 1986;32:preceding 383].
4. Wilde MI, McTavish D: Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
5. McTavish D, Buckley MM, Heel RC: Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991;42:138-170.
6. Stedman CAM, Barclay ML: Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-978.
7. Andersson T, Holmberg J, Rohss K, et al: Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998;45:369-375.
8. Yasuda S, Ohnish A, Ogawa T, et al: Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994;32:466-473.
9. Hassan-Alin M, Andersson T, Bredberg E, Rohss K: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-670.
10. Huber R, Hartmann M, Bliesath H, Luhmann R, Steinijans VW, Zech K: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34(suppl 1):S7-S16.
11. Pue MA, Laroche J, Meineke I, De Mey C: Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575-578.
12. Cederberg C, Andersson T, Skanberg I: Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 1989;166:33-40.
13. Andersson T, Cederberg C, Heggelund A: The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991;3:45-52.
14. Mohamed AH, Hunt RH: The rationale of acid suppression in the treatment of acid-related disease. Aliment Pharmacol Ther 1994;8(suppl 1):3-10.
15. Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-351.
16. Ehrlich A, Lucker PW, Wiedemann A, Sander P, Huber R, Mascher H: Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 1999;21:47-51.
17. Londong W, Londong V, Cederberg C, Steffen H: Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983;85:1373-1378.
18. Howden CW, Hunt RH: The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990;4:25-33.
19. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997;24:65-70.
20. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, et al: Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997;62:619-628.
21. Jansen JB, Lundborg P, Baak LC, Greve J, Ohman M, Stover C, et al: Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 1988;29:75-80.
22. Pue MA, Laroche J, Meineke I, De Mey C: Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575-578.
23. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552-561.
24. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al: Interphenotype differences in disposition and effect on gastrin levels of omeprazole - Suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-518.
25. 12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999;13:453-458.
26. Dent J: Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion 1990;47(suppl 1):69-71.
27. Astra: Losec Capsules 10/20/40 mg. Prescribing Information 1998; United Kingdom.
28. Hartmann M, Theiss U, Huber R, Luhmann R, Bliesath H, Wurst W, Lucker PW: Twenty-four hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996;10:359-366.
29. Scholtz H: Comparison of the effects of lansoprazole, omeprazole and pantoprazole on 24-hour gastric pH in healthy males. S Afr Med J 1995;85:915.
30. Koop H, Kuly S, Flug M, Schneider A, Rose K: Comparison of 24-h intragastric pH and 24-hour gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole (abstract). Gut 1994;35(suppl 4):A79 (No 1172).
31. Dammann HG, Burkhardt F: Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999;11:1277-1282.
32. Simon B, Mueller P, Gatz G, Sander P: Equivalent effect of pantoprazole 40 mg and esomeprazole 40 mg o.d. on intra-esophageal pH in patients with symptomatic GERD. Am J Gastroenterol 2001;96(suppl 9):108.
33. Katz PO, Xue S, Castell DO: Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg, and lansoprazole 30 mg. Aliment Pharmacol Ther 2001;15:647-652.
34. Frazzoni M, De Micheli E, Grisendi A, Savarino V: Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: A pH-metric comparison. Aliment Pharmacol Ther 2002;16:35-39.
35. Langtry HD, Wilde MI: Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473-500.
36. Frazzoni M, De Micheli E, Grisendi A, Savarino V: Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: A pH-metric comparison. Aliment Pharmacol Ther 2002;16:35-39.
37. Thoring M, Hedenström H, Eriksson LS: Rapid effect of lansoprazole on intragastric pH: A crossover comparison. Scand J Gastroenterol 1999;34:341-345.
38. Katashima M, Yamanoto K, Tokuma Y, Hata T, Sawada Y, Iga T: Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokin 1998;23:19-26.
39. Galmiche JP, Zerbib F, Ducrotte P, Fournet J, Rampal P, Avasthy N, Humphries TJ: Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 2001;15:1343-1350.
40. Andersson T, Röhss K, Bredberg E, Hassan-Alin M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-1569.
41. Ohning GV, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH: Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:701-708.
42. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, et al: Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-867.
43. McCaffrey E: The acid test for formulary policy. Bus Health 1999;17(suppl A):19-24.
44. Armstrong, D: Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. Lancet 2000;356:610-612.
45. Holtmann G, Kaspari S, Bayer H, GERD study group: Superiority of pantoprazole (20 mg OD) to omeprazole MUPS (10 mg OD) in patients with mild gastroesophageal reflux disease (abstract). Gut, in press.
46. Armstrong D: Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. Lancet 2000;356:610-612.
47. Guyatt GH, Sackett DL, Cook DJ: Users' guides to the medical literature. 2. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993;270:2598-2601.
48. Brouwer WBF, Rutten EFH: GVS geeft verkeerde signalen. ESB 2001;86:884-886.
49. van Busschbach JJ, van Hout BA: Snel verdiend: Nieuwe medicatie kan kosteneffectief zijn. Medisch Contact 2001;56:1815-1817.
50. Vicari F, Belin J, Marek L: Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux esophagitis: Results of a French multicentric double-blind comparative trial (abstract). Gastroenterology 1998;114:A324.
51. Pilotto A, Franceschi M, Leandro G, Di Mario F, Valerio G: Comparison of omeprazole, lansoprazole, and pantoprazole in the treatment of elderly patients with esophagitis (abstract). Gastroenterology 1999;116:A283.
52. Hotz J, Gangl A, Heinzerling H: A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis (abstract). Gastroenterology 1996;110(suppl):A136.
53. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ: An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
54. Scholten T, Gatz G: Pantoprazole 40 mg (Pan-to) relieves primary reflux symptoms more rapidly than omeprazole MUPS 20 mg (Ome) in patients with severe GERD symptomatology (abstract). Gastroenterology 2000;118:A1303.
55. Eissele R, Moennikes H, Braun W, Arnold R: Gastrointestinal (GI) symptoms in patients with mild gastro-esophageal reflux disease (GERD) - Effect of pantoprazole (Panto) (abstract). Gastroenterology 2000;118:A1231.
56. Scholten T, Gatz G, Sander P: Superior symptom relief of pantoprazole 40 mg compared to omeprazole MUPS 20mg in patients with severe heartburn. Gastroenterol 2001;120(suppl 1):A440.
57. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-464.
58. Kroes RM, Numans ME, Jones RH, De Wit NJ, Verheij RJM: Gastro-oesophageal reflux disease in primary care: Comparison and evaluation of existing national guidelines and development of uniform European guidelines. Eur J Gen Pract 1999;5:88-97
59. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-1030.
60. Howden CW, Burget DW, Hunt RH: A meta-analysis to predict gastric ulcer healing from acid suppression (abstract). Gastroenterology 1991;100:A85.
61. Lauritsen K, Rutgersson K, Bolling E, Brunner G, Eriksson S, Frison L, Galmiche JP, Thomson ABR, Walan A, Archambault AP, Gudjonsson H, Bailey RJ, Bianchi Porro G: Omeprazole 20 or 40 mg daily for healing of duodenal ulcer? Eur J Gastroenterol Hepatol 1992;4:995-1000.
62. Beker JA, Bianchi P, Bigard MA, Delle F, Devis G, Gouerou H, Maier C: Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:407-410.
63. Spencer CM, Faulds D: Esomeprazole. Drugs 2000;60:321-329.
64. Dobrilla G, Piazzi L, Fiocca R: Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: A randomized, multicenter, double-masked trial. Clin Ther 1999;21:1321-1332.
65. Dekkers CPM, Beker JA, Thjodleifsson B, et al: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. Aliment Pharmacol Ther 1999;13:179-186.
66. Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, Eriksson S: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
67. Valenzuela JE, Kogut DG, McCullough AJ, Colon P Jr, Shah U, Whipple J, Gilde LR, Simon TJ: Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: A multicenter, randomized, double-blind study. Am J Gastroenterol 1996;91:2516-2522.
68. Witzel L, Gutz H, Huttemann W, Schepp W: Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995;9:19-24.
69. Dekkers CP, Beker JA, Thjodleifsson B, et al: Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - A European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998;12:789-795.
70. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
71. Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PD: Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993;7:501-507.
72. Laursen LS, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E, Fenger C, Lauritsen K: Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind, randomized dose-finding study. Scand J Gastroenterol 1995;30:839-846.
73. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-912.
74. Astra Pharma Inc. Losec product monograph; in: Gillis MC (ed): Compendium of Pharmaceuticals and Specialties. Ottawa, Canadian Pharmacists Association, 1998.
75. Solvay Pharma Inc/Byk Canada Inc: Pantoloc Product Monograph; in Gillis MC (ed): Compendium of Pharmaceuticals and Specialties. Ottawa, Canadian Pharmacists Association, 1998.
76. Moss SF, Arnold R, Tytgat GNJ, Spechler SJ, Delle Fave G, Rosin D, et al: Consensus statement for management of gastroesophageal reflux disease. J Clin Gastroenterol 1998;27:6-12.
77. van Rensburg CJ, Honiball PJ, Grundling HD, van Zyl JH, Spies SK, Eloff FP, Simjee AE, Segal I, Botha JF, Cariem AK, Marks IN, Theon I, Bethke TD: Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996;10:397-401.
78. Chiba N: Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11(suppl B):66-73.
79. Bardhan KD, van Rensburg C, Gatz G: Comparison of pantoprazole (Panto) 20 mg versus omeprazole (Ome) 20 mg in patients with mild gastroesophageal reflux disease (GERD) (abstract). Can J Gastroenterol 1999;13(suppl B):154B.
80. Korner T, Suhl DE, Schutze K, Wien AT, van Leendert RJM, Zwijndrecht NL, et al: Comparable efficacy of pantoprazole 40 mg vs. omeprazole MUPS 40 mg in patients with GERD II/III. Can J Gastroenterol, in press.
81. Bochenek W, Miska D, Beg M: Efficacy of pan-toprazole in reflux erosive esophagitis (EE) is dose related (abstract). Digestion 1998;59(suppl 3):601.
82. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998;115:1335-1339.
83. Bardhan KD, Van Rensburg C: Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1585-1591.
84. Scholten T, Hole U, Gatz G: Similar reduction of symptom load within 4 weeks of treatment with pantoprazole 40 mg or esomeprazole 40 mg in patients with moderate to severe GERD. Can J Gastroenterol, in press.
85. Eissele R, Gatz G, Hole U: Equivalent efficacy of pantoprazole 40 mg and esomeprazole 40 mg in patients with GERD. Can J Gastroenterol, in press.
86. Dupas JL, Houcke P, Samoyeau R, et al: Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol 2000;25:245-250.
87. Sharma VK, Leontiadis GI, Howden CW: Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole. Aliment Pharmacol Ther 2001;15:227-231.
88. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Colllins DW, Whipple J, et al: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249-1258.
89. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-665.
90. Kromer W, Horbach S, Luhmann R: Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis. Pharmacology 1999;59:57-77.
91. Jones R, Bytzer P: Review article: Acid suppression in the management of gastro-oesophageal disease - An appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001;15:765-772.
92. Byrne MF, Murray FE: Formulary management of proton pump inhibitors. Pharmaco-economics 1999;16:225-246.
93. Panto™ IV Product Monograph.